"A 2.5% Week over Week Growth Rate Doubles Gross and Net Revenues every 30 WEEKS. $60 MILLION RUN RATE Today.
IN 30 Weeks, $120 MIllion Revenue Run Rate. 60 Weeks = $180 Million Run Rate. ----
BIIB has a 28 PE. - -----. Multiply 28 x $180 Million. " Your extrapolations are way over the top. Even the sell-side analysts are predicting only $79.1 million in gross revenues for FY ending 9/30/2013. Then you tell us to multiply your wildly inflated Avanir's gross revenues by the PE ratio of another company! But I think 4-5 times net revenues would be more than fair for a buyout price.
BioTech's which do not have FDA APPROVAL are valued at 3 x Peak Revenue Multiples. AVNR has FDA Approval and will likely be close to BE by calendar YE with an EARNINGS GROWTH RATE which is off the CHART thereafter.
I can assure you, any offer less than $2Billion (i.e., $15 per share) is a complete non-starter for TROWE, INGALLS, FMR, Blackrock etc.).